Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
6,262
datasets available to search
ShareScore release 0.9.0
Dataset results
6,262 results for “Treatment efficacy”
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
ClinicalTrials.gov study NCT01636687. IPD Sharing: UNDECIDED. Countries: 5. Publications: 6.
A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines
ClinicalTrials.gov study NCT05048342. IPD Sharing: YES. Countries: 1. Publications: 0.
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
ClinicalTrials.gov study NCT02941926. IPD Sharing: YES. Countries: 38. Publications: 5.
Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia
ClinicalTrials.gov study NCT04362813. IPD Sharing: UNDECIDED. Countries: 6. Publications: 2.
Data from: Modelling the potential efficacy of treatments for white-nose syndrome in bats
<p class="western">1. The fungal disease white-nose syndrome (WNS) has caused mass mortality in some species of North American bats during hibernation. </p> <p class="western">2. We use population viability models to test if a hypothetical WNS treatment or management action could facilitate the recovery of WNS-affected little brown myotis (<i>Myotis lucifugus</i>) populations. We modelled scenarios altering three parameters: (1) WNS severity (population growth rate of WNS-affected populations; λ<sub>WNS</sub>); (2) proportion of population treated; and (3) treatment improvement in winter survival (TIWS). </p> <p class="western">3. Our models predict that a treatment or management action that targets an entire population with a TIWS of 40% (the average TIWS in bat trials to date) will cause a population to stabilize or increase if WNS causes an annual decline of less than 70% (i.e. λ<sub>WNS</sub>>=0.30). However, for severe WNS (λ<sub>WNS</sub>=0.10), the TIWS must be at least 54% to cause the population to stabilize or increase. Where only a proportion of a WNS-affected population is treated, population stability is much harder to achieve unless the impact of WNS attenuates over time.</p> <p class="western">4. Our models suggest that a treatment or management action only facilitates the recovery of WNS-affected populations if WNS is mild, a large proportion of bats can be treated, TIWS is high, and/or WNS severity attenuates over time.</p> <p class="western"><span>5. </span><i>Synthesis and applications</i><i><span>.</span></i><span> We mode</span><span><span>lled</span></span><span> the predicted abundance trajectory of white-nose syndrome (WNS)-affected little brown myotis (</span><i><span>Myotis lucifugus</span></i><span>) populations </span><span><span>in response to hypothetical treatment or management actions. Our two types of models incorporate the complete range of possible scenarios varying three parameters: (1) population growth rate of the WNS-affected population</span></span><span><span>, (2) the improvement in winter </span></span><span><span>survival associated with the </span></span><span><span>treatment or management action, and (3) the proportion of the population treated. </span></span><span><span><span><span>We suggest that our models, which can be explored using online Shiny applications, should be used in the planning phase of treatment or management action programs for WNS.</span></span></span></span></p>
Genetic variants affecting NQO1 protein levels impact on efficacy of idebenone treatment in Leber hereditary optic neuropathy
<p>Fastq files with complete sequencing of NQO1 gene after PCR amplification for cell lines harboring m.11778G>A/MT-ND4 or m.3460A>G/MT-ND1 and controls.</p>
Data about upper limb kinematics to test the efficacy of Action Observation Treatment
<p>The dataset contains the upper-limb kinematics collected in 40 participants before and after a short-term immobilization of the right arm. Three reach-to-grasp movements were required, targeting an object placed a) frontally at the level of the shoulders (A_low), b) frontally above the head (A_high), or c) laterally at the level of the shoulders (L_low). These movements were intended to test different degrees of freedom of the shoulder joint.</p> <p>Half of the participants underwent a virtual-reality action observation treatment (see Rizzolatti et al, Neuroscience and Biobehabioral Reviews, 2021), while the control group underwent a non-motor VR stimulation.</p>
Figure 1 in Efficacy of low-dose EarthTec QZ treatment for the control of New Zealand mud snails Potamopyrgus antipodarum in a hatchery environment
Figure 1. Diagram of the split-plot study design.
The Efficacy of Azithromycin in the Treatment of Influenza A infection: A Systematic Review
<p>Background:</p> <p>The WHO recommendation against the use of macrolides reflects the little low-quality evidence about the effect of azithromycin (AZ) on influenza A infection. Considering recent reports about AZ use despite the WHO's unfavorable recommendations, we aimed to test the evidence for the usage of AZ in the treatment of influenza A infection.</p> <p>Methods:</p> <p>Various online databases were searched till August 2023 and thorough text and evidence evaluation resulted in selecting 7 studies.</p> <p>Results:</p> <p>The selected reports included randomized control trials (two), cohort (three), case/control (one) studies, and one case report. Pooling of the results was unattainable due to the variability among studies in patient criteria, study outcomes, and study designs. Based on the limited reports with insufficient evidence, a recommendation for the use of AZ in the treatment regimen was not possible despite the associated reduction in inflammatory cytokines by AZ administration and the absence of significant adverse effects or mortality in hospital-admitted or ICU patients. While these findings support the current guidelines for the treatment of influenza A infection, the evidence behind these guidelines and treatment characteristics were illustrated.</p> <p>Conclusion:</p> <p>AZ shows a potential symptom improvement and pro-inflammatory laboratory indices in influenza A patients. Another positive aspect is the absence of complications associated with AZ administration to critically ill patients and acceptable prognosis. However, it is crucial to have more quality research on this matter that focuses on the indication of the use of AZ, and the timing of initiation, dosage, and duration of treatment while monitoring adverse events.</p>
Dataset for comparison of the efficacy of different drug combinations for the treatment of patients with triple negative breast cancer.
<p>Dataset for comparison of the efficacy of different drug combinations for the treatment of patients with triple negative breast cancer.</p>
Dataset for: Efficacy of prescribed fire as a fuel reduction treatment in the Colorado Front Range
<p>Prescribed fires are an important management tool for reducing fuels and returning fire to the landscape. However, rarely are changes in fuels fully quantified using pre- to post-prescribed fire measurements, and those studies that do exist show variable results. In the southern Rockies, little literature exists on the impacts of prescribed fires, thus we examined multiple prescribed fires in northern Colorado to understand fire effects and changes in fuel complexes. Most prominently, prescribed fires influenced litter, duff, and rotten coarse woody debris but did not influence other surface fuels. Crown base height increased and tree density decreased, while basal area was relatively unimpacted. Season of burning impacted fire effects as substrate burn severity, bole char, and crown volume scorched were highest in summer and fall. Continued monitoring of prescribed fires is critical to understand the influence of prescribed fire on wildfires and ultimately improving prescribed fire outcomes.</p>
The Safety and Efficacy of vBloc Therapy Delivered by the Maestro Rechargeable System for the Treatment of Obesity
ClinicalTrials.gov study NCT01327976. IPD Sharing: NO. Countries: 2. Publications: 2.
Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal
ClinicalTrials.gov study NCT00865020. IPD Sharing: Not stated. Countries: 16. Publications: 3.
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
ClinicalTrials.gov study NCT02418585. IPD Sharing: Not stated. Countries: 5. Publications: 16.
Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain
ClinicalTrials.gov study NCT01559259. IPD Sharing: YES. Countries: 1. Publications: 1.
Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.
ClinicalTrials.gov study NCT01498679. IPD Sharing: YES. Countries: 3. Publications: 1.
Evaluation of Efficacy and Safety of Symbicort® as an add-on Treatment to Spiriva® in Patients With Severe COPD.
ClinicalTrials.gov study NCT00496470. IPD Sharing: Not stated. Countries: 9. Publications: 4.
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
ClinicalTrials.gov study NCT04688164. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS)
ClinicalTrials.gov study NCT01600716. IPD Sharing: Not stated. Countries: 8. Publications: 1.
Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis
ClinicalTrials.gov study NCT00790023. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.